Finanzen von Altimmune Inc (ALT)ALTAltimmune Inc

Evaluating the bottom line, Altimmune Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -28.87%, provide a clear picture of how effectively ALT converts its operational activities into shareholder value.

In the context of the broader market, ALT competes directly with industry leaders such as ARVN and EPRX. With a market capitalization of $571.88M, it holds a significant position in the sector. When comparing efficiency, ALT's gross margin of N/A stands against ARVN's 96.40% and EPRX's N/A. Such benchmarking helps identify whether Altimmune Inc is trading at a premium or discount relative to its financial performance.

Altimmune has shown a gross margin of 100% in recent quarters, indicating strong potential profitability once revenues increase. However, it has reported significant net losses, with a net income of -$22,825,000 for Q2 2026.